Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR-LLD in Multiple Myeloma
NCT06087653Phase 2Recruiting
- Sponsor
- Starton Therapeutics
- Start
- Oct 2023
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in multiple myeloma (MM), sponsored by Starton Therapeutics. Started Oct 2023; status: recruiting.
02
Drugs
lenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06087653.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06087653.